Ironwood Pharmaceuticals Begin Period Cash Flow Over Time
| IRWD Stock | USD 3.53 0.03 0.84% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Ironwood Pharmaceuticals Performance and Ironwood Pharmaceuticals Correlation. Ironwood |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ironwood Pharmaceuticals. If investors know Ironwood will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ironwood Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Earnings Share (0.01) | Revenue Per Share 2.393 | Quarterly Revenue Growth (0.20) | Return On Assets 0.1305 |
The market value of Ironwood Pharmaceuticals is measured differently than its book value, which is the value of Ironwood that is recorded on the company's balance sheet. Investors also form their own opinion of Ironwood Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ironwood Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ironwood Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ironwood Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ironwood Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Begin Period Cash Flow Analysis
Compare Ironwood Pharmaceuticals and related stocks such as Neurocrine Biosciences, Amphastar P, and Collegium Pharmaceutical Begin Period Cash Flow Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NBIX | 6.4 M | 54.1 M | 50.1 M | 63.8 M | 44.8 M | 31 M | 74.2 M | 83.3 M | 259.2 M | 147.2 M | 115.5 M | 190.3 M | 344 M | 270.7 M | 284.2 M |
| AMPH | 53.8 M | 53.8 M | 53.7 M | 50.2 M | 53.6 M | 67.8 M | 66.1 M | 72.4 M | 67.5 M | 88.2 M | 75.5 M | 94.5 M | 126.6 M | 156.3 M | 86.8 M |
| COLL | 11.9 M | 11.9 M | 11.9 M | 11.9 M | 7.6 M | 1.6 M | 95.7 M | 153.2 M | 118.8 M | 146.6 M | 170 M | 176.7 M | 189 M | 176.2 M | 124.7 M |
| ANIP | 1.8 M | 38.2 M | 57.2 M | 11 K | 11.1 M | 169 M | 154.7 M | 32.4 M | 36.1 M | 48 M | 67.4 M | 12.9 M | 105.3 M | 53.2 M | 37.4 M |
| ALKS | 3.1 M | 38.4 M | 83.6 M | 97 M | 167.6 M | 224.1 M | 181.1 M | 186.4 M | 191.3 M | 266.8 M | 203.8 M | 273 M | 337.5 M | 292.5 M | 307.1 M |
| ITCI | 13.7 M | 13.7 M | 13.7 M | 15.6 M | 35.2 M | 61.3 M | 47.2 M | 48.6 M | 37.8 M | 54.9 M | 107.6 M | 61.4 M | 93.8 M | 150.4 M | 157.9 M |
| PCRX | 7.2 M | 26.1 M | 46.2 M | 10.1 M | 12.5 M | 37.5 M | 57 M | 35.9 M | 54.1 M | 132.5 M | 78.2 M | 100 M | 585.6 M | 104.1 M | 89.8 M |
| AVDL | 1000 K | 8.2 M | 3.5 M | 2.7 M | 6.6 M | 39.8 M | 65.1 M | 39.2 M | 16.6 M | 9.3 M | 9.8 M | 71.7 M | 50.7 M | 74 M | 77.7 M |
| ASRT | 300 K | 22.5 M | 24 M | 29.1 M | 244.7 M | 488.7 M | 101.1 M | 117.7 M | 126.9 M | 110.9 M | 42.1 M | 20.8 M | 36.8 M | 64.9 M | 63.8 M |
| ESPR | 12.5 M | 3.4 M | 1.6 M | 6.5 M | 56.5 M | 85 M | 77.3 M | 38.2 M | 34.5 M | 37 M | 167.1 M | 305 M | 258.9 M | 124.8 M | 87.7 M |
Ironwood Pharmaceuticals and related stocks such as Neurocrine Biosciences, Amphastar P, and Collegium Pharmaceutical Begin Period Cash Flow description
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.My Equities
My Current Equities and Potential Positions
| Ironwood Pharmaceuticals | IRWD |
| Classification | Obamacare Repeal |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 3.53
Check out Ironwood Pharmaceuticals Performance and Ironwood Pharmaceuticals Correlation. For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Ironwood Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.